Acadia Pharmaceuticals (ACAD) Earnings Preview: Mizuho Sees Q1 Nuplazid Sales of $120M, Hopes to Hear Updates on Review of Nuplazid for Alzheimer's, Reiterates Neutral Rating
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD), ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
